PARIS, Jan. 7 (Reuters) – French health authorities on Friday authorized early access to a new treatment for COVID-19, Xevudy (sotrovimab) from GlaxoSmithKline GSK.L, believing that this monoclonal antibody could help fight the Omicron variant of the coronavirus.
Xevudy, which is administered intravenously, is intended for adults and adolescents 12 years of age and older infected with COVID-19 and at risk of severe form.
In a press release, the High Authority for Health (HAS), the body which authorizes the treatment, explains that “unlike the previous ones, it presents a mechanism of action which allows us to hope that its effectiveness will be maintained on variants, including the Omicron variant “.
Two other treatments of this type were already authorized in France: Ronapreve, from Roche ROG.S and Regeneron REGN.O, and Evusheld, from AstraZeneca AZN.L.
The European Medicines Agency authorized the marketing of Xevudy on December 17.
(Written by Sophie Louet, edited by Bertrand Boucey)
(([email protected]; General Information Department 01 49 49 53 68;))
– .
